Paul Chaplin

This inventor holds 39 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Vaccine Development. Top assignee: Bavarian Nordic A/s. Active years: 2004-2021.

USPTO Granted Patents = 39 (Patent Applications = 8)

% Patents Active = 53.8

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 3.2

ph-index = 17

Forward Citations = 633(Granted Patents)

Location History:

München, DE (2009 - 2012)
Munich, DE (2004 - 2013)
Gräfelfing, DE (2014 - 2016)
Gafelfing, DE (2017)
Grafelfing, DE (2013 - 2020)
Kvistgaard, DK (2021)

Company Filing History:

39 out of 134

Bavarian Nordic A/s

patents

Years Active: 2004-2021

Loading Chart...

Areas of Expertise:

Modified Vaccinia Virus

Vaccination

Respiratory Syncytial Virus

HIV Immunization

Poxviral Vectors

Immune Response

Neonatal Vaccines

Recombinant Technology

Immunogenicity

Tetanus Toxin

Viral Vectors

Infection Control

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10946089 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2021-03-16),

2. 10532094 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2020-01-14),

3. 10124058 - Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine (2018-11-13),

4. 10111946 - Poxviral vectors for low antibody response after a first priming immunization (2018-10-30),

5. 9717787 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2017-08-01),

6. 9707291 - Single high dose of MVA induces a protective immune response in neonates and infants (2017-07-18),

7. 9480738 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2016-11-01),

8. 9463238 - Recombinant poxvirus vector comprising tetanus toxin fragment C (2016-10-11),

9. 9265823 - Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents (2016-02-23),

10. 8808709 - Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents (2014-08-19),

11. 8470598 - Modified Vaccinia Ankara virus variant and cultivation method (2013-06-25),

12. 8372622 - Modified vaccinia virus ankara for the vaccination of neonates (2013-02-12),

13. 8323661 - Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) (2012-12-04),

14. 8309098 - Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs) (2012-11-13),

15. 8268329 - [object Object] (2012-09-18),

Title: Paul Chaplin - Innovative Inventor from Munich

Introduction: Paul Chaplin is a renowned inventor based in Munich, Germany, known for his groundbreaking contributions to various industries.

Latest Patents: Paul Chaplin holds several patents in the fields of technology, healthcare, and renewable energy, showcasing his diverse range of expertise and innovative mindset.

Career Highlights: With a career spanning over two decades, Paul Chaplin has worked with leading research institutions and multinational companies, consistently pushing the boundaries of innovation and creating solutions to complex challenges.

Collaborations: Throughout his career, Paul Chaplin has collaborated with top universities, research institutions, and forward-thinking companies, fostering a culture of innovation and knowledge sharing.

Conclusion: Paul Chaplin's passion for innovation, coupled with his dedication to creating a positive impact on society, solidifies his position as a pioneering inventor in the global landscape of technology and beyond.